News & Events

Armune BioScience, Inc. Announces the Closing of Series A Round of Financing

Funds will support the growth of commercial operations and research and development initiatives geared towards new tests in prostate, lung, and breast cancers. KALAMAZOO, MICH. September 07, 2016 — Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the closing of […]

Armune BioScience, Inc. Announces an Investment by the University of Michigan Investment Fund

$5 Million Series A investment round helps Armune, the developer of APIFINY, prepare for long term growth. KALAMAZOO, MICH. September 6, 2016 — Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the University of Michigan MINTS program has recently […]

Armune BioScience, Inc. Announces Tell Your Dad Campaign For National Prostate Cancer Awareness Month

KALAMAZOO, MICH. August 29, 2016 – Armune BioScience announced today the release of the Tell Your Dad campaign to coincide with Prostate Cancer Awareness Month. Anchored by a Presidential Proclamation, National Prostate Cancer Awareness Month is celebrated across the country with screenings, health fairs, media appearances, and other health education and outreach activities. The purpose […]

Armune BioScience, Inc. Receives State of Florida Clinical Laboratory License

Aeterna Zentaris Helps Coordinate Launch Plan in the Promotion of APIFINY, the Only Cancer Specific, Non-PSA Blood Test Available to Assess the Risk for the Presence of Prostate Cancer, to the Florida Market KALAMAZOO, MICH. August 8, 2016 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess […]

West Michigan is destination for life sciences startups

In its 2016 Annual Research Report, the Michigan Venture Capital Association revealed “Michigan-based venture capital firms have more capital under management than ever before: $2.2 billion, a 47 percent increase in capital used to power Michigan’s entrepreneurial economy in the last five years.” The report identified life sciences as one of the top two sectors […]

Armune BioScience to Participate in MultiPlan’s Networks, Expanding Access to APIFINY

KALAMAZOO, MI, March 31, 2016 – Armune BioScience, an emerging leader in cancer diagnostics, has recently completed a national Ancillary Service Agreement with MultiPlan, Inc. Under the new Agreement, APIFINY® will participate in the PHCS Network, MultiPlan’s national primary network, the MultiPlan Network, MultiPlan’s national complementary network, and ValuePoint by MultiPlan® a national discount card network used […]

Armune BioScience, Inc. Announces Closing of Series A Round of Financing

KALAMAZOO, MICH. March 30th, 2016 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the final close of its $4 million Series A financing. “We are pleased to successfully complete our Series A financing,” said David Esposito, […]